Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0J1HB
|
|||
Drug Name |
PF-06840003
|
|||
Synonyms |
3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione; 198474-05-4; PF06840003; 2,5-Pyrrolidinedione, 3-(5-fluoro-1H-indol-3-yl)-; 3-(5-fluoro-indol-3-yl)-pyrrolidine-2,5-dione; SCHEMBL5463464; GTPL9565; CTK0A0183; DTXSID00630149; MXKLDYKORJEOPR-UHFFFAOYSA-N; KS-000008MY; EX-A1186; EOS200271; AKOS027252536; CS-6186; AS-51973; HY-101111; 3-(5-Fluoro-1H-indol-3-yl)-pyrrolidine-2,5-dione
Click to Show/Hide
|
|||
Indication | Glioma [ICD-11: 2A00.0; ICD-9: 191] | Phase 1 | [1] | |
Company |
iTeos Therapeutics Gosselies, Belgium Pfizer New York, NY
|
|||
Structure |
Download2D MOL |
|||
Formula |
C12H9FN2O2
|
|||
Canonical SMILES |
C1C(C(=O)NC1=O)C2=CNC3=C2C=C(C=C3)F
|
|||
InChI |
1S/C12H9FN2O2/c13-6-1-2-10-7(3-6)9(5-14-10)8-4-11(16)15-12(8)17/h1-3,5,8,14H,4H2,(H,15,16,17)
|
|||
InChIKey |
MXKLDYKORJEOPR-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 198474-05-4
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target Info | Inhibitor | [1] |
BioCyc | Superpathway of tryptophan utilization | |||
Tryptophan degradation | ||||
L-kynurenine degradation | ||||
Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde | ||||
NAD de novo biosynthesis | ||||
KEGG Pathway | Tryptophan metabolism | |||
Metabolic pathways | ||||
African trypanosomiasis | ||||
NetPath Pathway | TSLP Signaling Pathway | |||
IL5 Signaling Pathway | ||||
TGF_beta_Receptor Signaling Pathway | ||||
Pathwhiz Pathway | Tryptophan Metabolism | |||
Reactome | Tryptophan catabolism | |||
WikiPathways | Tryptophan metabolism | |||
Metabolism of amino acids and derivatives |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.